Suppr超能文献

曲格列酮而非吡格列酮影响ATP敏感性钾通道活性。

Troglitazone but not pioglitazone affects ATP-sensitive K(+) channel activity.

作者信息

Sunaga Y, Inagaki N, Gonoi T, Yamada Y, Ishida H, Seino Y, Seino S

机构信息

Department of Metabolism and Clinical Nutrition, Kyoto University Graduate School of Medicine, 54, Shogoin Kawahara-cho, Sakyo-ku, Kyoto, Japan.

出版信息

Eur J Pharmacol. 1999 Sep 17;381(1):71-6. doi: 10.1016/s0014-2999(99)00539-7.

Abstract

We compared the effects of the two thiazolidinedione derivatives, troglitazone and pioglitazone, on ATP-sensitive K(+) (K(ATP)) channel activities. Pancreatic beta-cell type and cardiac type K(ATP) channels were reconstituted in COS-1 cells (SV 40-transformed African green monkey kidney (AGMK) cells) by heterologously expressing sulfonylurea receptor 1 (SUR1) plus Kir6.2 and sulfonylurea receptor 2A (SUR2A) plus Kir6.2, respectively. Troglitazone inhibited [86Rb(+)] efflux in both K(ATP) channel types in the presence of metabolic inhibitors, which was confirmed by electrophysiological techniques. The [86Rb(+)] efflux increased by the channel openers diazoxide and pinacidil was abolished by troglitazone. In contrast, pioglitazone did not affect these channel activities in either type K(ATP) channel. These results suggest that troglitazone modulates the various cellular functions including insulin secretion by inhibiting the K(ATP) channels, while pioglitazone has no effect on K(ATP) channel activity.

摘要

我们比较了两种噻唑烷二酮衍生物——曲格列酮和吡格列酮对ATP敏感性钾(K(ATP))通道活性的影响。通过分别异源表达磺脲类受体1(SUR1)加Kir6.2和磺脲类受体2A(SUR2A)加Kir6.2,将胰腺β细胞型和心脏型K(ATP)通道在COS-1细胞(SV40转化的非洲绿猴肾(AGMK)细胞)中重组。在存在代谢抑制剂的情况下,曲格列酮抑制了两种K(ATP)通道类型中的[86Rb(+)]外流,这一点通过电生理技术得到了证实。通道开放剂二氮嗪和平尼地尔所增加的[86Rb(+)]外流被曲格列酮消除。相比之下,吡格列酮对任何一种K(ATP)通道类型的这些通道活性均无影响。这些结果表明,曲格列酮通过抑制K(ATP)通道来调节包括胰岛素分泌在内的各种细胞功能,而吡格列酮对K(ATP)通道活性没有影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验